ClinicalTrials.gg
CompletedNCT00219388Updated Mar 20, 2017

Efficacy and Safety of Treatment With Simdax® Versus Dobutrex® in Decompensated Heart Failure Patients.

A Phase 4 interventional study of Levosimendan in Heart Failure, sponsored by Orion Corporation, Orion Pharma. Completed at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-20.

Sponsored by Orion Corporation, Orion Pharma · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies testing simendan in Heart Failure — 2 open to participants now, 2 under way, 2 of them phase 3. Simendan · Heart Failure.

Enrollment
19th of 32
60 · median 76
Started
2002
with 1 other
Phase 4
14 of 32
none open now
Registered
5th of 32
by date

Among the 32 studies testing simendan in Heart Failure, this one is the 19th largest by enrollment, is one of 2 that started in 2002, is one of 14 in phase 4, and was the 5th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

2 of the 32 studies testing simendan in Heart Failure are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About simendan

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing simendan in Heart Failure, or all of them as a file.
02

Study summary

The purpose of this study is to compare the effects of levosimendan with dobutamine on heart function in patients suffering of severe chronic heart failure.

Read the detailed description

Patients with decompensate heart failure (NYHA III-IV) and in need of intravenous inotrop support and who fulfil all inclusion and no exclusion criteria will be randomised into the study in proportion 1:1. Although stratification will be done so patients treated with beta-receptor blocker carvedilol will be divided the same between the study groups.

All patients will receive infusions in parallell, one of the groups will receive active product (levosimendan or dobutamine) and the other will receive placebo (double-dummy technique).

Catheterisation for measurement of hemodynamic parameters will be performed according to routine methods at the clinic. The measurements of the hemodynamic variables will start 30 minutes before start of study drug infusion and will be finished 48 hours after start of infusion. The most important variables during the measurements is Cardiac Index (CI)and Pulmonary Capillary Wedge Pressure (PCWP).

Parallel registration will be done on ECG, blood pressure, blood frequency, central venous pressure, and lung artery pressure. Heart failure and other clinical symptoms will be registered continuously during 48 hours. Blood samples will be taken intermittent to record the blood values. Cogent rules for decreasing/increasing of the dose can be found in the study protocol, likewise rules for interruption or stoop for infusion.

Registration of side-effects will be done continuously. The recommendation for treatment for known side effects could be found in the protocol (section 5.3.4) and the protocol should be available during the study procedure.

One month after the study the patients will be followed up with a very careful examination and also of the amount of visits and reason for visits to hospital during the past 30-35 days.

03

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • Safety
  • Efficacy
  • Levosimendan
  • Dobutamine
  • Intravenous
  • Invasive hemodynamics
  • Decompensated Heart Failure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Decompensated chronic heart failure of ischemic or non-ischemic origin, in class III to IV, despite optimised conventional treatment and who may benefit from intravenous positive inotropic agents as per the investigator's judgment.
  • Ongoing treatment with a beta-receptor blocking agent in a stable regimen for at least 3 months and at an optimal dose as per the investigator's judgment.
  • Left ventricular (LV) (EF) less than or similar to 35%.
  • CI \< 2.5 l/min/m2.
  • Mean PCWP >15 mmHg.

Main Exclusion Criteria:

  • Significant mechanical obstruction affecting ventricular filling and/or outflow.
  • Systolic blood pressure 85 mmHg or less at screening and/or baseline.
  • Heart rate 130 bpm or greater, persistent for at least 5 minutes at screening and/or baseline.
  • Severe angina pectoris during the 6 hours before screening and/or baseline.
  • Deterioration of chronic heart failure due to an acute myocardial infarction within 5 days before screening measurements.
  • Administration of Simdax within 1 month before baseline.
  • A history of Torsades de Pointes.
  • Evidence of severe renal insufficiency (serum creatinine > 450 μmol/l or on dialysis) at screening.
  • Significant hepatic impairment or elevation of liver enzymes to 5 times the of the analysing laboratory at screening.
  • Acute bleeding or severe anaemia.
  • Heart surgery within 3 months before baseline.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
60 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Compare the hemodynamic parameters Cardiac Index (CI) and Pulmonary Capillary Wedge Pressure (PCWP) from baseline to 24 hours, between the two groups.

Secondary outcomes

  1. Compare the efficacy and safety between the treatment groups, with regard to:

  2. • Changes in hemodynamic parameters from baseline to 24 and 48 hours.

  3. • Change in study subject's and investigator's assessment of symptoms of heart failure at 48 hours and 1-month follow-up.

  4. • Change in New York Heart Association (NYHA) classat 48 hours and 1-month follow-up.

  5. • Ability to continue treatment with β-receptor blocking agents.

  6. • Days alive and out of hospital during the 1-month follow-up period.

  7. • Change in B-type Natriuretic Polypeptide (BNP)at 24 and 48 hours and 1-month follow-up.

  8. • Proportion of treatment discontinuations and/or need for rescue therapy due to lack of efficacy.

07

Study locations

1 site
  • Cardiology Department, Sahlgrenska University Hospital
    Gothenburg, 413 45, Sweden
08

References and documents

Publications

  • Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, Lehtonen L; Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002 Jul 20;360(9328):196-202. doi: 10.1016/s0140-6736(02)09455-2. PubMed 12133653 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2002 and a completion of Apr 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2005
First posted
Sep 22, 2005
Start
Nov 2002
Completion
Apr 2005
Last update
Mar 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Mar 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00219388
First posted
Sep 22, 2005
Start date
Nov 2002
Completion
Apr 2005
Last update
Mar 20, 2017

Study contacts

Claes-Håkan Bergh, Assoc Prof
principal investigator · Institution of Cardiology, Sahlgrenska University Hospital, Sweden
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2005. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Simendan

Start the discussion